Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5221MR)

This product GTTS-WQ5221MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ5221MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13650MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ13029MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ1305MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ABT-555
GTTS-WQ264MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA 17-1A
GTTS-WQ1541MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-031
GTTS-WQ11102MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ11569MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ764MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AB0024
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW